Literature DB >> 25224769

Assessing clinical outcomes of patients with acute calculous cholecystitis in addition to the Tokyo grading: a retrospective study.

Wei-Chun Cheng1, Yen-Cheng Chiu2, Chiao-Hsiung Chuang3, Chiung-Yu Chen4.   

Abstract

The management of acute cholecystitis is still based on clinical expertise. This study aims to investigate whether the outcome of acute cholecystitis can be related to the severity criteria of the Tokyo guidelines and additional clinical comorbidities. A total of 103 patients with acute cholecystitis were retrospectively enrolled and their medical records were reviewed. They were all classified according to therapeutic modality, including early cholecystectomy and antibiotic treatment with or without percutaneous cholecystostomy. The impact of the Tokyo guidelines and the presence of comorbidities on clinical outcome were assessed by univariate and multivariate regression analyses. According to Tokyo severity grading, 48 patients were Grade I, 31 patients were Grade II, and 24 patients were Grade III. The Grade III patients had a longer hospital stay than Grade II and Grade I patients (15.2 days, 9.2 days, and 7.3 days, respectively, p < 0.05). According to multivariate analysis, patients with Grade III Tokyo severity, higher Charlson's Comorbidity Score, and encountering complications had a longer hospital stay. Based on treatment modality, surgeons selected the patients with less severity and fewer comorbidities for cholecystectomy, and these patients had a shorter hospital stay. In addition to the grading of the Tokyo guidelines, comorbidities had an additional impact on clinical outcomes and should be an important consideration when making therapeutic decisions.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Acute cholecystitis; Charlson’s Comorbidity Score; Tokyo guidelines

Mesh:

Year:  2014        PMID: 25224769     DOI: 10.1016/j.kjms.2014.05.005

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  7 in total

1.  Outcomes of early cholecystectomy (within 7 days of admission) for acute cholecystitis according to diagnosis and severity grading by Tokyo 2013 Guideline.

Authors:  İsmail Sert; Fuat İpekci; Ömer Engin; Muharrem Karaoğlan; Özhan Çetindağ
Journal:  Turk J Surg       Date:  2017-06-01

2.  The optimal treatment of patients with mild and moderate acute cholecystitis: time for a revision of the Tokyo Guidelines.

Authors:  Charlotte S Loozen; Maaike M Blessing; Bert van Ramshorst; Hjalmar C van Santvoort; Djamila Boerma
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

3.  Percutaneous cholecystostomy for severe (Tokyo 2013 stage III) acute cholecystitis.

Authors:  F Polistina; C Mazzucco; D Coco; M Frego
Journal:  Eur J Trauma Emerg Surg       Date:  2018-01-25       Impact factor: 3.693

4.  Prediction of the grade of acute cholecystitis by plasma level of C-reactive protein.

Authors:  Esin Kabul Gurbulak; Bunyamin Gurbulak; Ismail Ethem Akgun; Yigit Duzkoylu; Muharrem Battal; Mustafa Fevzi Celayir; Uygar Demir
Journal:  Iran Red Crescent Med J       Date:  2015-04-25       Impact factor: 0.611

5.  Factor Analysis Influencing Postoperative Hospital Stay and Medical Costs for Patients with Definite, Suspected, or Unmatched Diagnosis of Acute Cholecystitis according to the Tokyo Guidelines 2013.

Authors:  Aoi Hayasaki; Koji Takahashi; Takehiro Fujii; Koji Kumamoto; Koji Fujii; Eiichi Matsumoto; Shigeki Miyahara; Tsukasa Kusuta; Yoshinori Azumi; Shuji Isaji
Journal:  Gastroenterol Res Pract       Date:  2016-04-28       Impact factor: 2.260

6.  Factors Influencing Length of Stay in Cholecystectomy Patients in a Community Hospital.

Authors:  Monica Zipple; Eliza Slama; James Wilkie; Alicia Kieninger; Robert Robinson
Journal:  Spartan Med Res J       Date:  2017-12-19

7.  Operative complications and economic outcomes of cholecystectomy for acute cholecystitis.

Authors:  Christopher P Rice; Krishnamurthy B Vaishnavi; Celia Chao; Daniel Jupiter; August B Schaeffer; Whitney R Jenson; Lance W Griffin; William J Mileski
Journal:  World J Gastroenterol       Date:  2019-12-28       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.